Biopharma startup Rgenix said it has raised $40 million in Series C financing to further develop its clinical and pre-clinical oncology programs and for general corporate purposes.
New York City-based Rgenix has discovered several novel RNA-regulated cancer targets that drive tumor growth and cancer progression, according to its website. These targets regulate key components of the tumor microenvironment, including immune cells and cancer metabolism pathways.
Get the full story on our sister site, Drug Delivery Business.
The post Rgenix raises $40M to develop novel cancer drugs appeared first on MassDevice.
from MassDevice https://ift.tt/2QGedks
Cap comentari:
Publica un comentari a l'entrada